For adults with overweight or obesity, certain factors might influence weight loss after taking glucagon-like peptide 1 receptor agonists (GLP-1 RAs), according to a study published online July 9 in ...

Oxyntomodulin (OXM) is a peptide hormone released by intestinal L cells after food intake. It acts as a dual agonist of glucagon-like peptide 1 (GLP-1) and glucagon receptors, regulating appetite, ...

A study in Diabetes, Obesity and Metabolism has identified certain characteristics that might influence people's weight loss ...

A study in Diabetes, Obesity and Metabolism has identified certain characteristics that might influence people's weight loss ...

The mechanisms driving the cardiovascular and renal benefits of therapies targeting intestinal hormones in type 2 diabetes ...

A new study led by Ananda Basu, M.D., used novel non-radioactive, stable glucagon tracers for the first time to characterize glucagon metabolism in humans with and without Type 1 diabetes, providing ...

A study explored glucagon metabolism in humans with and without Type 1 diabetes using stable glucagon tracers. Findings reveal significant differences in splanchnic and leg glucagon metabolism.

A novel study using stable glucagon tracers reveals key findings in Type 1 diabetes metabolism, impacting treatment and management strategies.

Background: Intestinal hormones (incretins) such as GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) play a significant role in the regulation of blood glucose ...

Glucagon prescriptions for severe hypoglycemia rose in Medicaid beneficiaries with the introduction of newer products but likely met only a fraction of the high-risk population’s needs.

Learn more about the metabolic effects of liraglutide treatment in individuals with type 2 diabetes and obesity.